Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on February 14, 2023, regarding events occurring on February 8, 2023. The filing discloses the entry into a material definitive agreement to secure a revolving line of credit for general corporate purposes.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or margin data. The primary financial metric disclosed is the establishment of a new credit facility:
- Credit Facility Amount: Up to $150,000,000.
- Lender: UBS Bank USA.
- Interest Structure: Borrowings may be fixed or variable, calculated as the UBS rate plus an applicable percentage spread.
- Collateral: The line is secured by a first priority lien on the Company's accounts, securities, and investment property held with UBS Financial Services Inc.
Material Changes
The material change reported is the execution of the Credit Line Agreement. This creates a direct financial obligation and an off-balance sheet arrangement (until drawn) secured by the Company's existing cash and marketable securities held at UBS. The agreement allows the Company to draw funds at any time but requires the posting of additional collateral if the value of existing collateral declines below maintenance requirements.
Guidance, Risks, and Contingencies
The filing contains no specific financial guidance or management commentary regarding future performance. Key risks and contingencies associated with the agreement include:
- Default Provisions: Upon customary events of default, all amounts become immediately due and payable without demand.
- Lender Discretion: UBS has the right to demand full or partial payment and terminate the Credit Line at any time in its discretion and without cause.
- Collateral Liquidation: In the event of default, UBS has the right to liquidate, transfer, or sell the collateral to satisfy obligations.
- Forward-Looking Statements: The report includes standard disclaimers that forward-looking statements are subject to risks and uncertainties detailed in the Company's Form 10-K.
Investor Verification Checklist
- Verify the specific interest rate spreads and fees detailed in the full Credit Line Agreement (Exhibit 10.1).
- Confirm the current value of the Company's cash and marketable securities held at UBS to assess the immediate borrowing capacity.
- Review the Company's most recent Form 10-K for existing debt obligations and liquidity ratios to understand the impact of this new facility.
- Monitor future filings for any draws on the credit line or changes in collateral maintenance requirements.